About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. It focuses on oncology and acute radiation syndrome. It offers Entolimod, Mobilan, CBL0137, and SA-702. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Buffalo, NY.

At the moment the company generates 2M USD in revenues.

On its last earning announcement, the company reported a loss of -0.39$ per share.

The book value per share is 0.01$

Cleveland BioLabs, Inc. website


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
2M - -5M -303.80% -4M -0.39 - - 11M 0.01 -5M - -5M